Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
Trevena, Inc. (TRVN) is a biopharmaceutical company focused on medicines for central nervous system (CNS) disorders, and its news flow reflects both clinical and corporate developments. Company press releases highlight progress with its approved product OLINVYK (oliceridine) injection for acute pain in adults and its pipeline of investigational CNS candidates, including TRV045, TRV250 and TRV734.
News updates frequently cover clinical and preclinical data for TRV045, a highly selective S1P1 receptor modulator in development for neuropathic pain secondary to diabetic peripheral neuropathy and under exploration for epilepsy through collaborations such as the NIH-supported Epilepsy Therapy Screening Program. Trevena reports results from proof-of-concept studies, preclinical pain and epilepsy models, and ongoing formulation and toxicology work that inform the potential path toward later-stage development.
Investors can also follow commercial and strategic updates related to OLINVYK, including reductions in commercial support, strategic reviews of alternatives for the product, and discussions of how OLINVYK remains available for purchase while the company evaluates options such as sale, license, divestiture or discontinuation of U.S. commercial sales.
Trevena’s news includes capital markets and corporate actions, such as private placements, warrant exercises, royalty-based financing amendments, and a 1-for-25 reverse stock split. The company has reported decisions by the Nasdaq Hearings Panel to delist its common stock, the suspension of trading on Nasdaq, and the commencement of trading on the OTC Pink Open Market and subsequent identification of the OTC Expert Market as the trading venue in SEC filings.
For readers tracking TRVN, the news stream provides context on clinical progress, regulatory and safety information for OLINVYK, financing arrangements, cost-cutting measures, board and management changes, and the company’s ongoing strategic review of its assets.
Trevena, Inc. (Nasdaq: TRVN) announced that Wake Forest Baptist Health Medical Center will participate in the VOLITION study to assess the impact of OLINVYK (oliceridine) on postoperative respiratory, gastrointestinal, and cognitive outcomes. The study, led by Cleveland Clinic, will enroll approximately 200 adults and is expected to begin patient enrollment in Q3 2021. Mark A. Demitrack, M.D., stated that the results could enhance understanding of OLINVYK's clinical value, aiming to address significant clinical needs related to pain management.
Trevena, Inc. (TRVN) reported a net loss of $14 million for Q2 2021, up from $6.2 million the previous year. The company has achieved 35 formulary approvals for OLINVYK, with a goal of 100 by year-end. Ongoing studies for OLINVYK and TRV027 aim to enhance understanding of their efficacy in various medical conditions. Cash reserves stand at $91 million, sufficient to cover operational expenses through Q4 2022. Trevena's stock has been added to Russell 2000, Russell 3000, and Russell Microcap indexes, enhancing its visibility among investors.
Trevena, Inc. (Nasdaq: TRVN) announced an exploratory analysis revealing that patients treated with OLINVYK (oliceridine) are approximately 50% less likely to experience adverse events compared to those treated with IV morphine at equal analgesic levels. Conducted using data from the OLINVYK Phase 3 program, the analysis showed a significant odds ratio indicating lower treatment-emergent adverse events for OLINVYK, suggesting a favorable benefit-risk profile for post-operative pain management. The publication can be found in the relevant medical journal and was authored by Dr. Gregory B. Hammer.
Trevena, Inc. (Nasdaq: TRVN) will announce its second quarter financial results on August 12, 2021, before the market opens. A conference call will follow at 8:00 a.m. ET, featuring key executives including President Carrie Bourdow and CFO Barry Shin. Trevena focuses on developing novel medicines for central nervous system disorders, with one approved product, OLINVYK® (oliceridine) injection, and a pipeline including four investigational drug candidates targeting migraine and opioid use disorder.
Trevena, Inc. (Nasdaq: TRVN) has initiated patient enrollment for the ACTIV-4 Host Tissue trial, focusing on COVID-19 treatments. TRV027, an innovative AT1 receptor selective agonist, aims to combat the damaging effects of COVID-19 on the lungs and blood clotting. The trial will include around 1,600 patients at over 50 sites across the U.S. TRV027 has previously shown promise in clinical settings with a favorable safety profile. The study's goal is to evaluate the effectiveness of various agents, including TRV027, in preventing severe outcomes in hospitalized COVID-19 patients.
Trevena, Inc. (Nasdaq: TRVN) announced a published health economic model for its drug OLINVYK (oliceridine) in the Journal of Comparative Effectiveness Research. The model shows significant cost savings for hospitals using OLINVYK over IV morphine for postoperative pain management. The analysis indicates a reduction in total care costs per 1,000 patients due to fewer adverse effects noted in Phase 3 trials. This publication is expected to aid formulary reviews, supporting the drug's utilization in acute pain management.
Trevena, Inc. (TRVN) has partnered with Nhwa to begin a Phase 3 trial for OLINVYK (oliceridine) injection in China, targeting acute pain management. The trial, which has enrolled its first patient, aims to include around 160 participants following abdominal surgery. Trevena expects to gain 10% royalty on net sales and anticipates receiving approval and commercialization milestones. The study's primary endpoint focuses on pain relief efficacy, with safety assessed via various adverse events. Successful completion may lead to regulatory filing for OLINVYK in China.
Trevena, Inc. (Nasdaq: TRVN) has announced a new study evaluating the respiratory effects of OLINVYK in elderly and obese patients. The Phase 1 trial, led by Dr. Albert Dahan, will compare OLINVYK with IV morphine using an innovative clinical utility function analysis. Enrollment is expected in Q3 2021, aiming for topline data by YE 2021. This study is part of Trevena’s strategy to enhance evidence for OLINVYK’s clinical profile and assess its therapeutic potential in managing acute pain.
Trevena, Inc. (Nasdaq: TRVN) announced its addition to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective June 28, 2021. This inclusion signifies a positive recognition for Trevena, reflecting the value from the launch of its product OLINVYK and progress in its pipeline. The move is expected to enhance the company's visibility, broaden its shareholder base, and improve stock liquidity, according to President and CEO Carrie Bourdow. Russell indexes manage approximately $9 trillion in assets.
Trevena, Inc. (Nasdaq: TRVN) announced that the National Institute on Drug Abuse (NIDA) has resumed patient recruitment for the proof-of-concept study of TRV734, a novel oral treatment for opioid use disorder (OUD). The study, paused in March 2020 due to COVID-19, aims to evaluate TRV734's efficacy in reducing withdrawal symptoms. The clinical trial will involve approximately 50 patients and assess both safety and tolerability. TRV734 targets the mu-opioid receptor and shows promise in preclinical studies, potentially offering a better-tolerated option than existing treatments.